Shire plc recently delivered data at the American Academy of Allergy, Asthma & Immunology annual meeting on its Cuvitru drug, which treats patients with primary immunodeficiency.
“Shire is focused on innovating on behalf of patients with PI so they can more easily manage their condition,” Paul Blanchfield, U.S. head of immunology at Shire, said in a statement. “Cuvitru allows for fewer infusion sites and shorter infusion durations than other conventional SCIG options, without compromising on efficacy or safety. We hope this means an improved overall treatment experience for PI patients and greater flexibility in managing their condition.”
Patients reported improved treatment satisfaction with the drug, according to the statement.
The U.S. Food and Drug Administration first approved Cuvitru in September 2016. The drug, which can be tailored to patient and physician preference, is part of the company’s expansive immunoglobulin therapy portfolio.
“Many patients require IG replacement therapy throughout their lives, making it important to consider the patient’s experience in addition to the treatment’s ability to limit or reduce infections,” Dr. Mark R. Stein, FAAAAI, medical director at Allergy Associates of the Palm Beaches, said in the statement. “These data advance our understanding of how we can best support patients throughout their PI journey.”
Alerts Sign-up